Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Furmonertinib + Savolitinib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Furmonertinib | AST2818|AST2818|Alflutinib | EGFR Inhibitor 3rd gen 26 | Furmonertinib (alflutinib) is a third-generation EGFR inhibitor that targets both EGFR activating mutations and T790M, potentially leading to tumor growth inhibition (PMID: 33780662, PMID: 35662408). | |
Savolitinib | HMPL-504|AZD6094|AZD-6094|Volitinib | MET Inhibitor 59 | Savolitinib (AZD6094) is a selective MET inhibitor, which inhibits MET kinase activity, resulting in decreased downstream signaling, and may inhibit growth of MET-expressing tumors (PMID: 25248999, PMID: 32027846, PMID: 30952639). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|